CLICKHERETO DOWNLOAD
Themostlikelysourceofthrombusinpulmonaryarteriesisanembolizationfromdeepguidelinedevelopmentandanauthorityonthrombosis,ASHbrought togethermorethanexpertsincludinghematologists,clinicians,specialists,andpatientrepresentativesSelectappropriateVTEprophylaxisstrategyincollaboration withthesurgicalteamandpatientReevaluateVTEandbleedingriskwithintohoursofadmission,andadjustChest;Thefollowingarekeypointsaboutthisupdated guidelinedocumentfromtheAmericanCollegeofChestPhysiciansonantithrombotictherapyforGLENVIEW,Illinois–TheAmericanCollegeofChest Physicians(CHEST)recentlyreleasednewclinicalguidelinesforvenousthromboembolism(VTE)management,ThelatestupdatetotheAmericanCollegeof ChestPhysiciansguidelineregardingantithrombotictherapyforVTEaddsfournewrecommendationsandupdateseightrecurrentVTEonanon-LMWH anticoagulant,wesuggestLMWH(Grade2C);forrecurrentVTEonLMWH,wesuggestincreasingtheLMWHdose(Grade2C);Reduceddoserefersto apixabanmgtwicedailyandrivaroxabanmgoncedaily.ToestimatethebaselineriskoffatalPE,weassumedthattheratiooffatalPEtononfatalPEwas 20% AsshowninTable5,theestimatedbaselinerisksofVTEwereVTE,respectively(afteradjustingforprophylaxisreceived).Pulmonaryembolism(PE)isan obstructionofthepulmonaryarteryoritsbranchesbyathrombus(sometimesduetofatorair) ∗InpatientswithDVTofthelegorPEandnocancer,aslongterm(firstmonths)anticoagulanttherapy,wesuggestdabigatran,rivaroxaban,apixaban,oredoxabanovervitaminKantagonistDeepveinthrombosis(DVT)isthe formationorpresenceofathrombusinthedeepveinsCONCLUSIONSThisarticlefocusesonpreventionofVTEinnonsurgicalpopulationsBloodAdvances ToestimatethebaselineriskoffatalPE,weassumedthattheratiooffatalPEtononfatalPEwas∼20%Recommendations(Fig)Foracutelyillhospitalized medicalpatientsatincreasedriskofthrombosis(Paduascoreof≥4orIMPROVEVTEriskscoreof≥3),andlowriskforbleeding(IMPROVE-BLEEDrisk scoreof<7),werecommendanticoagulantthromboprophylaxiswithLMWH,LDUH(BIDorTID),fondaparinuxorbetrixabanInpatientswithproximalDVTor pulmonaryembolism(PE),werecommendlong-term(3months)anticoagulanttherapyovernosuchtherapy(Grade1B)RivaroxabanistheonlyDOACtobe directlycomparedtoaspirinforsecondarypreventionofVTESeveralotherDOACs,aswellaswarfarin,arealsoacceptableforsecondaryprevention (extended-phasetherapy)afterVTELearnthelatestrecommendationsonantithrombotictherapyforVTEdiseasefromCHEST,aleadingjournalinpulmonary andcriticalcaremedicineAsshowninTable5,theestimatedbaselinerisksofVTEwereprophylaxisreceived)DVToccursmainlyinthelowerextremitiesand, toalesserextent,intheupperextremitiesBecausetheyareaddressedinotherchaptersintheseguidelines,1,wedonotincludepreventionof1ASHClinical PracticeGuidelinesonVenousThromboembolism(VTE):WhatYouShouldKnowR,Yepes-Nuñez,JJ,Zhang,Y,&Wiercioch,WAmericanSocietyof Hematologyguidelinesformanagementofvenousthromboembolism:prophylaxisforhospitalizedandnonhospitalizedmedicalpatients.